Immatics NV
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more
Market Cap & Net Worth: Immatics NV (IMTX)
Immatics NV (NASDAQ:IMTX) has a market capitalization of $1.30 Billion ($1.30 Billion) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9125 globally and #4449 in its home market, demonstrating a -7.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immatics NV's stock price $9.68 by its total outstanding shares 134063829 (134.06 Million).
Immatics NV Market Cap History: 2018 to 2026
Immatics NV's market capitalization history from 2018 to 2026. Data shows growth from $1.31 Billion to $1.30 Billion (0.11% CAGR).
Index Memberships
Immatics NV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.03% | #252 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #967 of 3165 |
Weight: Immatics NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immatics NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immatics NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
30.36x
Immatics NV's market cap is 30.36 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.31 Billion | $3.77 Million | -$31.44 Million | 348.49x | N/A |
| 2019 | $1.39 Billion | $18.45 Million | -$31.74 Million | 75.57x | N/A |
| 2020 | $1.45 Billion | $31.25 Million | -$229.35 Million | 46.29x | N/A |
| 2021 | $1.80 Billion | $34.76 Million | -$95.06 Million | 51.83x | N/A |
| 2022 | $1.17 Billion | $172.83 Million | $37.51 Million | 6.76x | 31.13x |
| 2023 | $1.41 Billion | $54.00 Million | -$96.99 Million | 26.14x | N/A |
| 2024 | $953.19 Million | $155.84 Million | $15.22 Million | 6.12x | 62.64x |
| 2025 | $1.41 Billion | $46.36 Million | -$188.69 Million | 30.36x | N/A |
Competitor Companies of IMTX by Market Capitalization
Companies near Immatics NV in the global market cap rankings as of March 19, 2026.
Key companies related to Immatics NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Immatics NV Historical Marketcap From 2018 to 2026
Between 2018 and today, Immatics NV's market cap moved from $1.31 Billion to $ 1.30 Billion, with a yearly change of 0.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.30 Billion | -7.81% |
| 2025 | $1.41 Billion | +47.68% |
| 2024 | $953.19 Million | -32.48% |
| 2023 | $1.41 Billion | +20.90% |
| 2022 | $1.17 Billion | -35.19% |
| 2021 | $1.80 Billion | +24.56% |
| 2020 | $1.45 Billion | +3.75% |
| 2019 | $1.39 Billion | +6.12% |
| 2018 | $1.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Immatics NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.30 Billion USD |
| MoneyControl | $1.30 Billion USD |
| MarketWatch | $1.30 Billion USD |
| marketcap.company | $1.30 Billion USD |
| Reuters | $1.30 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.